Rubraca OverviewRucaparib (brand name Rubraca /rubrk/ roo-BRAH-k) is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It was discovered as part of a collaboration between scientists working at the Northern Institute of Cancer Research and Medical School of Newcastle University and Agouron Pharmaceuticals in San Diego, California. It is being developed by Clovis Oncology. In December 2016,...
Read more Rubraca Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Rucaparib
Recent Rubraca Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 200mg, 250mg, 300mg
NDC Database Records for Rubraca: (3 results)Sorted by National Drug Code
- 69660-201 Rubraca 200 mg Oral Tablet, Film Coated by Clovis Oncology, Inc.
- 69660-202 Rubraca 250 mg Oral Tablet, Film Coated by Clovis Oncology, Inc.
- 69660-203 Rubraca 300 mg Oral Tablet, Film Coated by Clovis Oncology, Inc.